BioMedNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) Receives IND Clearance from FDA, Represents First Ever Natural Killer Immunotherapy Trial for a Particular Cancer
INmune Bio (NASDAQ: INMB), a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease, announced that its Investigational New Drug (“IND”) application for INKmune(TM), a novel natural killer (“NK”) cell immunotherapy, has been cleared by the U.S. Food and Drug Administration (“FDA”) for a phase 1/2 open-label clinical trial for the treatment of metastatic castration-resistant prostate cancer (“mCRPC”). According to the announcement, this is the first NK immunotherapy trial in men with mCRPC, as far as the company is aware. The trial, which will begin enrolling patients later this year, will focus on determining short-…
